Virologic Impact of Radiotherapy in Hepatitis C Virus‐Infected Patients With Hepatocellular Carcinoma

Angelidakis, Georgios; Krishnan, Sunil; Cabrera, Nicolo L.; Jiang, Ying; Pushparaji, Bala; Kaseb, Ahmed O.; Torres, Harrys A.

doi:10.1002/hep.31114

Cited by 4 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early cancer serum tumor marker detection is an attractive method for surveillance and early diagnosis of hepatocellular carcinoma and could help reduce the mortality of HCC ( 1 , 6 ). This approach allows a noninvasive, objective, and reproducible evaluation.…”

Section: Discussionmentioning

confidence: 99%

“…Although many molecular biomarkers involved in HCC have been identified, the mechanism behinds its development remains unclear. There have been continuous efforts to discover HCC-associated autoantibody biomarkers for use as early diagnostic biomarkers, and several tumor-associated autoantibodies were recently suggested as early predictors of HCC before diagnosis ( 6 , 7 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells

Huang

Zeng

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

As an important global medical problem, hepatocellular carcinoma (HCC) has been recognized as the most frequent primary liver cancer and a leading cause of death among patients with cirrhosis. Surveillance of HCC using serum markers aims to reduce the disease-related mortality of HCC. MUC16 (mucin 16, also known as carbohydrate antigen 125, CA125) has been predicted as a tumor biomarker for many cancer types. Based on the high frequency mutation rate in a database from the Cancer Genome Atlas (TCGA), we investigated the effects of MUC16 knockdown and the regulatory profile of MUC16 in HepG2 and Huh7 cell lines. Knockdown of MUC16 was conducted via siRNA transfection, and the proliferation of cells was not affected by CCK8 assay results. Moreover, decreasing the expression of MUC16 enhanced the migration and invasion of cells, as shown by wound healing and transwell assays. Furthermore, RNA-seq was used to investigate the effect of MUC16 knockdown on the gene expression profile of HepG2 and Huh7 cells. Our study demonstrated the significant role of MUC16 in the inhibition of the migration and invasion of HepG2 and Huh7 cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells

Huang

Zeng

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Unfortunately, the disease carries an extremely poor prognosis, further exacerbating recovery. 4,5 Currently, treatment options for HCC are limited and primarily include surgical liver resection, chemotherapy, and liver transplantation. Early detection modalities for HCC are also restricted to the aforementioned options.…”

Section: Introductionmentioning

confidence: 99%

“…The majority of HCC cases occur in patients with underlying liver diseases, predominantly hepatitis B virus (HBV) or hepatitis C virus (HCV) infections or alcohol abuse. Unfortunately, the disease carries an extremely poor prognosis, further exacerbating recovery. , Currently, treatment options for HCC are limited and primarily include surgical liver resection, chemotherapy, and liver transplantation. Early detection modalities for HCC are also restricted to the aforementioned options .…”

Section: Introductionmentioning

confidence: 99%

Enhancing Targeted Therapy in Hepatocellular Carcinoma through a pH-Responsive Delivery System: Folic Acid-Modified Polydopamine-Paclitaxel-Loaded Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Nanoparticles

Wu,

Wang,

Peng

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

Currently, there is an inherent contradiction between the multifunctionality and excellent biocompatibility of anticancer drug nanocarriers, which limits their application. Therefore, to overcome this limitation, we aimed to develop a biocompatible drug delivery system for the treatment of hepatocellular carcinoma (HCC). In this study, we employed poly(3-hydroxybutyrate-co-3hydroxyvalerate) (PHBV) as the fundamental framework of the nanocarrier and utilized the emulsion solvent evaporation method to fabricate nanoparticles loaded with paclitaxel (PTX), known as PTX-PHBV NPs. To enhance the tumortargeting capability, a dopamine self-polymerization strategy was employed to form a pH-sensitive coating on the surface of the nanoparticles. Then, folic acid (FA)-targeting HCC was conjugated to the nanoparticles with a polydopamine (PDA) coating by using the Michael addition reaction, resulting in the formation of HCC-targeted nanoparticles

show abstract

QNZ alleviated hepatocellular carcinoma by targeting inflammatory pathways in a rat model

et al. 2021

View full text Add to dashboard Cite

Virologic Impact of Radiotherapy in Hepatitis C Virus‐Infected Patients With Hepatocellular Carcinoma

Cited by 4 publications

References 5 publications

Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells

Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells

Enhancing Targeted Therapy in Hepatocellular Carcinoma through a pH-Responsive Delivery System: Folic Acid-Modified Polydopamine-Paclitaxel-Loaded Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Nanoparticles

QNZ alleviated hepatocellular carcinoma by targeting inflammatory pathways in a rat model

Contact Info

Product

Resources

About